Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital

October 16, 2024 6:50 AM EDT

RBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $181.00 (from $178.00) while maintaining a Outperform rating.

The analyst comments "JNJ delivered a Q3 beat on sales/EPS that sent the stock up ~2% today. The company delivered +5.6% y/y underlying... More

Johnson & Johnson (JNJ) PT Raised to $170 at Stifel

October 15, 2024 2:22 PM EDT

Stifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $160.00) while maintaining a Hold rating.

The analyst comments "Helped by better-than-expected 3Q24 Pharmaceutical division performance, both JNJ 3Q24 sales and EPS outperformed Stifel and consensus. And looking ahead, the company's... More

Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)

October 15, 2024 8:20 AM EDT

Citi analyst Joanna Wuensch reiterated a Buy rating and $180.00 price target on Johnson & Johnson (NYSE: JNJ).

The analyst comments "JNJ delivered 3Q24 revenue of $22.5B (up 5.6% organic) ahead of consensuss $22.2B. Innovative Medicine sales were $14.58B (up 6.7% organic ex-Covid-19, versus consensuss... More